LENZ ral­lies pres­by­opia aware­ness with eye­care pro­fes­sion­als ahead of FDA sub­mis­sion

LENZ Ther­a­peu­tics is clear on the ben­e­fits of pre-com­mer­cial mar­ket­ing for its pres­by­opia eye drops, bol­stered by pos­i­tive Phase 3 news this week. The new da­ta back its con­fi­dence — and plans to file for FDA ap­proval midyear — in its late-stage can­di­date and main­stream mar­ket po­ten­tial.

The biotech soft-launched a cam­paign for eye care pro­fes­sion­als in Feb­ru­ary, and will ful­ly launch mid-month with the ad­di­tion of 30 more op­tom­e­try and oph­thal­mol­o­gy ex­perts join­ing the “Eye Am” ef­fort. The aware­ness web­site us­es strik­ing pho­tographs of lead­ing eye care doc­tors tak­en by com­mer­cial pho­tog­ra­ph­er and di­rec­tor Will Strawser, along with state­ments about the doc­tors’ ex­cite­ment and ex­pec­ta­tions around new pres­by­opia re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER